CPT® Code 90734

Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use

The CPT® Code 90734 refers to a specific type of meningococcal conjugate vaccine designed to protect against meningococcal disease caused by the bacterium Neisseria meningitides. This vaccine is a quadrivalent formulation, meaning it targets four distinct serogroups: A, C, W, and Y. The vaccine utilizes either diphtheria toxoid (MenACWY-D) or a mutant form of diphtheria toxin known as CRM197 (MenACWY-CRM) as a carrier protein to enhance the immune response. Meningococcal disease can lead to severe health complications, including septicemia and meningitis, and is transmitted through respiratory secretions. The vaccine works by introducing capsular polysaccharide antigens from each of the four serogroups, which are conjugated to the carrier protein. This process stimulates the immune system to produce antibodies that recognize and combat these pathogens. Notably, MenACWY-CRM is approved for use in infants aged 2 to 8 months, particularly for those at increased risk of meningococcal disease, while MenACWY-D is indicated for children aged 9 to 12 months. It is important to note that this code specifically accounts for the supply of the vaccine itself; the administration of the vaccine via intramuscular injection is reported separately.